Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on February 14, 2024, covering events occurring on February 9, 2024, and February 13, 2024. The company is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California.
Key Financial Metrics and Debt
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The report focuses exclusively on debt obligations:
- Debt Instrument: Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited.
- New Drawdown: On February 13, 2024, the company drew an additional $500,000 under the note.
- Repayment Date: The maturity date for the outstanding principal balance and accrued fees is extended to May 9, 2024.
Material Changes
The primary material change reported is the execution of a Sixth Amendment to the Secured Note on February 9, 2024. This amendment extended the repayment deadline from the original date to May 9, 2024. Subsequently, the company utilized available credit under this facility to secure $500,000 in funding.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to various risk factors detailed in the company's periodic SEC reports. No specific operational guidance, revenue outlook, or management commentary regarding future performance is provided in this document. The filing highlights the obligation to repay the note principal and accrued fees by the new May 9, 2024, deadline.
Investor Verification Checklist
- Verify the total outstanding principal balance and accrued interest on the Secured Note as of the filing date.
- Review the full text of the Sixth Amendment (Exhibit 10.1) for specific interest rates, conversion terms, and covenants.
- Assess the company's liquidity position and ability to repay the $500,000 drawdown plus existing obligations by May 9, 2024.
- Check subsequent filings for any further amendments or defaults related to the Juvenescence note.